⌘K
Loading ticker…
Liminatus Pharma, Inc. Class A Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a 3-month relative strength percentile of 6 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 25. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 11.0%, relative volume 0.27×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
6 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
LIMN is in a stage 4 downtrend, week 4. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -38.9% / -84.8%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
LIMN appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $9K notional.
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $9K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LIMN Jan avg: -9.80% median: -9.80% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN Feb avg: -54.02% median: -54.02% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN Mar avg: -32.05% median: -32.05% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN Apr avg: 18.73% median: 18.73% win: 100% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN May avg: -32.86% median: -32.86% win: 0% σ: 18.69% n: 2 2025-05-02 → 2026-05-29 | LIMN Jun avg: 105.34% median: 105.34% win: 100% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 (current) | LIMN Jul avg: -43.77% median: -43.77% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN Aug avg: -56.78% median: -56.78% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN Sep avg: -38.38% median: -38.38% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN Oct avg: -16.77% median: -16.77% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN Nov avg: -25.18% median: -25.18% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 | LIMN Dec avg: -41.35% median: -41.35% win: 0% σ: 0.00% n: 1 2025-05-02 → 2026-05-29 |